In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Fibrocell Science Inc (FCSC), with a price target of $22. The company’s shares opened today at $2.20.
Pantginis commented:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $22 price target. We point out that the large delta between the current share price and our price target is driven by the company’s relatively low share count. Further, we believe that the current share price does not reflect, despite the low patient numbers, the ability of FCX-007 to address RDEB patients’ needs, as well as the accelerated potential from a regulatory standpoint, including a Priority Review Voucher (PRV).”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.3% and a 34.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fibrocell Science Inc with a $22 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.45 and a one-year low of $1.45. Currently, Fibrocell Science Inc has an average volume of 993K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fibrocell Science, Inc. is an autologous cell and gene therapy company, which focuses on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. The company was founded on December 28, 1995 and is headquartered in Exton, PA.
